BMS’ Opdivo wins new NICE lung cancer backing by Selina McKee | Sep 18, 2020 | News | 0 The drug has been approved for routine NHS commissioning for squamous or non-squamous NSCLC Read More
US priority review for Keytruda/chemo combo in first-line squamous NSCLC by Selina McKee | Jul 3, 2018 | News | 0 US regulators have assigned a priority review to MSD’s application to market the immunotherapy Keytruda in combination with chemotherapy as a first-line treatment for squamous non-small cell lung cancer (NSCLC). Read More